These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33167835)

  • 21. A biomarker study in long-lasting amnestic mild cognitive impairment.
    Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D
    Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
    Frings L; Hellwig S; Bormann T; Spehl TS; Buchert R; Meyer PT
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1442-1448. PubMed ID: 29546632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
    Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
    J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
    Banzo I; Jiménez-Bonilla J; Ortega-Nava F; Quirce R; Martínez-Rodríguez I; de Arcocha-Torres M; Rodríguez E; Vázquez JL; Sánchez PJ; Martínez-Amador N; Ibañez-Bravo S; Carril JM
    Nucl Med Commun; 2014 Mar; 35(3):238-44. PubMed ID: 24240196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment.
    Brück A; Virta JR; Koivunen J; Koikkalainen J; Scheinin NM; Helenius H; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1567-72. PubMed ID: 23801168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apathy is associated with increased amyloid burden in mild cognitive impairment.
    Marshall GA; Donovan NJ; Lorius N; Gidicsin CM; Maye J; Pepin LC; Becker JA; Amariglio RE; Rentz DM; Sperling RA; Johnson KA
    J Neuropsychiatry Clin Neurosci; 2013; 25(4):302-7. PubMed ID: 24247857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between cytokine levels in the cerebrospinal fluid and 11C-Pittsburgh compound B retention in patients with mild cognitive impairment.
    Abe Y; Kimura N; Takahashi R; Gotou M; Mizukami K; Uchida H; Matsubara E
    Geriatr Gerontol Int; 2017 Nov; 17(11):1907-1913. PubMed ID: 28261965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
    Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.
    Grimmer T; Riemenschneider M; Förstl H; Henriksen G; Klunk WE; Mathis CA; Shiga T; Wester HJ; Kurz A; Drzezga A
    Biol Psychiatry; 2009 Jun; 65(11):927-34. PubMed ID: 19268916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship Between the Japanese Version of the Montreal Cognitive Assessment and PET Imaging in Subjects with Mild Cognitive Impairment.
    Eguchi A; Kimura N; Aso Y; Yabuuchi K; Ishibashi M; Hori D; Sasaki Y; Nakamichi A; Uesugi S; Jikumaru M; Sumi K; Shimomura T; Matsubara E
    Curr Alzheimer Res; 2019; 16(9):852-860. PubMed ID: 31385770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of T
    Boles Ponto LL; Magnotta VA; Menda Y; Moser DJ; Oleson JJ; Harlynn EL; DeVries SD; Wemmie JA; Schultz SK
    J Neuropsychiatry Clin Neurosci; 2020; 32(4):352-361. PubMed ID: 32283991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
    Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
    J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.